Update on Stock Availability of Trulicity® (dulaglutide) 1.5mg

Update 1 November 2023

Eli Lilly New Zealand (Lilly) wishes to advise of expected limited availability of the Type 2 Diabetes (T2D) medication Trulicity®(dulaglutide), due to global supply pressures.

Lilly is focused on maintaining supplies of Trulicity in New Zealand for existing patients. The supply situation is expected to continue to remain dynamic until the end of 2024. During this time, patients in New Zealand may experience delays or interruptions in fulfilling their Trulicity prescriptions.

Lilly is in frequent contact with wholesalers, and we are closely monitoring stock levels. We are releasing stock to wholesalers as equitably as possible. Given the expected limited availability of Trulicity, Lilly does anticipate potential delays, interruptions and/or shortages in stock available through wholesalers and at pharmacies during this time.For the latest information on the Special Authority criteria for Trulicity, please refer to the PHARMAC website: (www.pharmac.govt.nz).(1)

Healthcare professionals are asked to consider future uncertainties with Trulicity product availability on patients when making treatment choices, particularly for new patient initiations. Lilly continues to work closely with Pharmac to minimise patient impact. For details on alternative treatments subsidised for type 2 diabetes in New Zealand, please refer to Dulaglutide (Trulicity): Supply issue - Pharmac | New Zealand Government.(1)

Healthcare professionals requiring further medical or scientific information about Trulicity may contact the Lilly Medical Information team on 0800 500 056 (operating hours Monday to Friday, 11am – 7pm NZDT).

  1. New Zealand Pharmaceutical Schedule, https://pharmac.govt.nz, last accessed 1 November 2023

  2. MEDSAFE, Trulicity Consumer Medicine Information, https://www.medsafe.govt.nz/Consumers/CMI/t/trulicity.pdf, last accessed 1 November 2023

TRULICITY® is a registered trademark of Eli Lilly and Company (NZ Limited).

Please review full Data Sheet before prescribing. Full Data Sheet can be accessed at www.medsafe.govt.nz or on request by calling 0800 500 056.

TRULICITY® (dulaglutide 1.5mg/0.5mL solution for injection, pre-filled pen [autoinjector]). PRESCRIPTION MEDICINE. TRULICITY is funded under the New Zealand Pharmaceutical Schedule. Special Authority Criteria apply.

INDICATIONS – TRULICITY is indicated for adult patients with Type 2 diabetes as 1) an adjunct to diet and exercise to improve glycaemic control; and 2) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in those with either established cardiovascular disease or multiple risk factors for cardiovascular disease. CONTRAINDICATIONS – Hypersensitivity to dulaglutide or any of the excipients. PRECAUTIONS – should not be used in patients with Type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; severe gastrointestinal disease – not recommended; acute pancreatitis – discontinue treatment if suspected; hypoglycaemia – combining treatment with sulfonylurea or insulin may increase risk; congestive heart failure – limited therapeutic experience; Use in Pregnancy Category B3. ADVERSE EFFECTS Clinical Trials Experience – Very Common (≥10%) gastrointestinal disorders (nausea, vomiting and diarrhoea), hypoglycaemia (in combination with insulin non-/secretagogues and/or insulin); Common (≥1 and <10%) abdominal pain, decreased appetite, dyspepsia, fatigue, hypoglycaemia (as monotherapy), constipation, flatulence, abdominal distention, GERD, eructation, immunogenicity, atrial fibrillation. DOSAGE AND ADMINISTRATION – Dosage: Adults (≥ 18 years): 1.5 mg once weekly, at any time of day, independently of meals. Elderly Patients (≥65 years): dose adjustment not required. Children and adolescents (<18 years): safety and effectiveness have not been established. Renal Impairment: no dose adjustment is required in mild, moderate or severe renal impairment; not recommended in end-stage renal disease. Hepatic Impairment: no dose adjustment required. Administration: subcutaneous injection in the abdomen, thigh or upper arm. Should not be administered intravenously or intramuscularly. Single-use in one patient only. Discard the pen once the injection is completed. Please review full Data Sheet before prescribing. Full Data Sheet is available on request from Eli Lilly. Eli Lilly and Company (NZ) Limited, PO Box 109 197, Newmarket, Auckland 1149. Phone 0800 500 056. Based on Data Sheet revised 09 June 2023. TRULICITY® is a registered trademark of Eli Lilly and Company.

Eli Lilly and Company (NZ) Limited. NZBN: 9429039560643. PO Box 109197 Newmarket, Auckland 1149, New Zealand. Prepared November 2023. PP-DG-NZ-0106. TAPS BG2648.